A trio of new studies yesterday in the New England Journal of Medicine report encouraging results on the effectiveness and durability of protection of COVID-19 vaccines against hospitalization and death, including teens.98% protection against ICU stay, life supportOne study, led by the Centers for Disease Control and Prevention's (CDC's) COVID-19 Response Team, involved 445 hospitalized COVID-19 patients 12 to 18 years old and 777 uninfected matched controls at 31 hospitals in 23 states from Jul 1 to Oct 25, 2021, after the emergence of the Delta (B1617.2) variant.
Seventeen case patients (4%) and 282 controls (36%) had received two doses of the Pfizer/BioNTech COVID-19 vaccine.Among case patients, 180 (40%) were admitted to an intensive care unit (ICU), and 127 (29%) needed life support.
Of all ICU patients, only two were fully vaccinated. Overall vaccine effectiveness (VE) against hospitalization was 94% (95% confidence interval [CI], 90 to 96).Among uninfected controls with COVID-like symptoms, VE was 95% (95% CI, 91 to 97), while it was 94% (95% CI, 89 to 96) among uninfected controls with no symptoms.
VE was 98% against ICU admission and 98% against requiring life support. Seven patients died, and 13 required extracorporeal membrane oxygen, all of whom were unvaccinated.Three-quarters of the COVID-19 patients had underlying chronic illnesses, and nearly half were Black or Hispanic (24% and 25%, respectively).On Oct 22, the researchers published interim findings from the study showing 93% VE for the Pfizer vaccine against COVID-related hospitalization among 179 12- to 18-year-old case patients at 19 sites in 16 states.Of the current study, the authors said, "In this real-world evaluation of the effectiveness of the